Osimertinib for Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Current Evidence.

Background: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has demonstrated efficacy across multiple treatment lines for patients with EGFR-mutated non-small cell lung cancer (NSCLC). However, the optimal treatment sequence and comparative effectiv...

Descripción completa

Detalles Bibliográficos

Publicado en:	Clinical Medicine Insights: Oncology Vol. 20; pp. 1 - 18
Autores principales:	Tang, Xiumei, Chen, Yanmei, Zhu, Yuan, Liu, Yuan, Li, Weimin, Wang, Wenzhao, Wang, Zhoufeng
Formato:	meta analysis research systematic review tables/charts Journal Article
Publicado:	Sage Publications Inc. 3/27/2026
Acceso en línea:	Ver este registro en EBSCOhost